The Leading Community for Trusted Peptide Research & Insights
Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the non-erythropoietic, tissue-protective domain of erythropoietin. Research focuses on neuropathic pain, small fiber neuropathy, sarcoidosis, and metabolic syndrome without stimulating red blood cell production.
Summary: Selectively activates the innate repair receptor (IRR/EPOR-betaCR heteromer), triggering tissue-protective and anti-inflammatory signaling without erythropoietic effects. Mechanisms (reported/proposed across domains): Pain / neuropathy • Activates the innate repair receptor (IRR), a heteromeric complex of EPOR and beta common receptor (betaCR), distinct from the classical...
Investigational - Phase 2/3 Clinical Data
Dose: 4 mg · Route: Subcutaneous (SC) · Frequency: 1× daily · Duration: 28 days (clinical trials)